Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00SJN
|
|||
| Former ID |
DIB002652
|
|||
| Drug Name |
HLL1-Fab-A3B3
|
|||
| Synonyms |
Milatuzumab-Fab-CEA-loaded dendritic cell vaccine (cancer); Milatuzumab-Fab-CEA-loaded dendritic cell vaccine (cancer), Immunomedics
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Investigative | [1] | |
| Company |
Immunomedics Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Carcinoembryonic antigen CEA (CD66e) | Target Info | . | [1] |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2836). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.